Opus Genetics is headquartered in Durham, Michigan.
Opus Genetics disclosed revenue of 10M USD for 2024 and 19M USD for 2023.
Opus Genetics has 18 employees.
Opus Genetics is a life science company.
Opus Genetics was founded in 2018.
8 Davis Drive Suite 220,
Durham, Michigan
27709
United States,
(984) 884-6030
www.opusgtx.com
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Opus Genetics' lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size and improve visual acuity. Opus Genetics was founded in 2018 and is based in Durham, Michigan.
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.0/yr) | # | 1 | - | - | - | - | - | 1 |
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 1 | ||||||||
| Financial | Deals |
|---|---|
|
Oppenheimer & Co. |
1 |
| Legal | Deals |
|---|---|
|
Hogan Lovells |
1 |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
